Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04418427 · ClinicalTrials.gov registry record · Phase 2
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2 study, sponsored by Adverum Biotechnologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT04418427 is a Phase 2 study that has completed, run by Adverum Biotechnologies. The registered enrollment target is 36 participants.
The verdict
NCT04418427, a Phase 2 study, has completed, sponsored by Adverum Biotechnologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
A Phase 2, Multi-Center, Randomized, Double-Masked\*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema \[INFINITY\]
Interventions
- BIOLOGICAL Aflibercept
- BIOLOGICAL 6E11 vg/eye of ADVM-022
- BIOLOGICAL 2E11 vg/eye of ADVM-022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04418427
The ClinicalTrials.gov registry entry for NCT04418427 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adverum Biotechnologies, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aflibercept is the first listed.
NCT04418427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04418427 about?
NCT04418427 is a clinical study titled "ADVM-022 Intravitreal Gene Therapy for DME". A Phase 2, Multi-Center, Randomized, Double-Masked\*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema \[INFINITY\]
What is the current status of trial NCT04418427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2020-05-28. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT04418427?
The interventions under investigation include: Aflibercept (BIOLOGICAL), 6E11 vg/eye of ADVM-022 (BIOLOGICAL), 2E11 vg/eye of ADVM-022 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04418427?
This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.